MDWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MediWound is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near short-term resistance, options sentiment is mildly bullish, and the company still faces revenue timing risk tied to BARDA/Department of War grants. With no strong proprietary buy signal today and no clear financial acceleration shown in the latest quarter, the better call is to wait rather than buy immediately.
MDWD closed at 15.15, essentially flat versus the previous close of 15.16, while the broader market was slightly down. The MACD histogram is positive and expanding, which supports near-term upward momentum. RSI_6 at 64.9 is moderately strong but not overbought. Moving averages are converging, suggesting a potential inflection point rather than a confirmed breakout. Price is trading just below R1 at 15.213 and above the pivot at 14.659, so the stock is sitting near resistance with limited immediate upside unless it clears 15.21 convincingly. Similar candlestick pattern data also points to weak short-term follow-through, including a projected -3.61% move over the next month.
["MACD is positive and expanding, showing improving short-term momentum.", "Options sentiment is mildly bullish with put-call ratios below 0.5.", "Analysts still keep Buy/Outperform ratings in place.", "Long-term pipeline value from EscharEx remains a meaningful upside driver."]
["No AI Stock Picker signal today.", "No SwingMax signal recently.", "Price is close to resistance at 15.213, limiting immediate upside.", "Revenue is still being impacted by lack of BARDA and Department of War grants.", "Oppenheimer noted full-year revenue guidance may be at risk due to BARDA timing.", "Similar-pattern trend data suggests weak next-month performance."]
Latest quarter was Q1 2026. Financially, the company posted lower revenue and a lower loss than some analysts expected, but revenue remains constrained by limited NexoBRID capacity and the absence of BARDA and Department of War grants. Management reiterated full-year revenue guidance of $24M-$26M, though that guidance is viewed as at risk because of grant timing. Overall, the latest quarter showed some cost/loss improvement but not strong top-line growth.
Recent analyst trend is mildly positive but less enthusiastic than before: Alliance Global cut its target to $22 from $25 and kept Buy, while Oppenheimer trimmed its target to $32 from $33 and kept Outperform. Both remain constructive on the long-term pipeline, especially EscharEx, but both also flagged Q1 revenue weakness and grant timing dependence. Wall Street’s pros view is that the pipeline could become transformative and support sustained profitability; the cons view is that near-term revenue visibility is weak and current growth depends on external grant timing.
